Segall Bryant & Hamill, LLC Biocryst Pharmaceuticals Inc Transaction History

Segall Bryant & Hamill, LLC

$5.57 Billion
Q2 2024

A detailed history of Segall Bryant & Hamill, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 1,526,481 shares of BCRX stock, worth $12.1 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

1,526,481

Previous 1,749,448 12.74%

Holding current value

$12.1 Million

Previous $8.89 Million 6.14%

% of portfolio

0.17%

Previous 0.17%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $920,853 - $1.51 Million	-222,967 Reduced 12.74%	1,526,481 $9.43 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $49,540 - $77,502	10,131 Added 0.58%	1,749,448 $8.89 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $1.39 Million - $1.89 Million	-278,669 Reduced 13.81%	1,739,317 $10.4 Million
Q3 2023 Nov 09, 2023	SELL	$6.71 - $7.92 $132,200 - $156,039	-19,702 Reduced 0.97%	2,017,986 $14.3 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $1.39 Million - $1.76 Million	199,834 Added 10.87%	2,037,688 $14.3 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $1.34 Million - $2 Million	168,855 Added 10.12%	1,837,854 $15.3 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $17.5 Million - $23.7 Million	1,668,999 New	1,668,999 $19.2 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $18.1 Million - $24.9 Million	1,681,189 New	1,681,189 $21.2 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $6.94 Million - $15.7 Million	879,417 Added 93.18%	1,823,209 $19.3 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $10.9 Million - $18.6 Million	943,792 New	943,792 $15.3 Million

Others Institutions Holding BCRX

# of Institutions

257

Shares Held

173M

Call Options Held

397K

Put Options Held

444K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.47B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Biocryst Pharmaceuticals Inc Transaction History